EcoDrugPlus

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSTUG00000025955
Gene Symbol: SRC
3 Cross references
186 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSSTUG00000012933
Gene Symbol: SRC
3 Cross references
186 Possible Orthologues:

Tgf-Beta Receptor Type-1

Ensembl ID : ENSSTUG00000000093
Gene Symbol: LOC115149427
3 Cross references
199 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSSTUG00000035236
Gene Symbol: LOC115169694
3 Cross references
150 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSSTUG00000005208
Gene Symbol: LOC115195639
3 Cross references
199 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSSTUG00000038441
Gene Symbol: LOC115157085
3 Cross references
150 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSSTUG00000014328
Gene Symbol: WEE1
3 Cross references
142 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSSTUG00000025529
Gene Symbol: WEE1
3 Cross references
142 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSSTUG00000016247
Gene Symbol: YES1
3 Cross references
202 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSSTUG00000042693
Gene Symbol: YES1
3 Cross references
202 Possible Orthologues:

Acetylcholinesterase-Like

Ensembl ID : ENSSTUG00000015731
Gene Symbol: LOC115198571
3 Cross references
227 Possible Orthologues:

Acetylcholinesterase-Like

Ensembl ID : ENSSTUG00000012983
Gene Symbol: LOC115194622
3 Cross references
227 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).